Provided by Tiger Trade Technology Pte. Ltd.

Warrior Met Coal LLC

91.80
-0.9200-0.99%
Post-market: 91.800.00000.00%19:30 EDT
Volume:612.18K
Turnover:56.42M
Market Cap:4.83B
PE:22.07
High:95.91
Open:94.14
Low:91.47
Close:92.72
52wk High:111.42
52wk Low:60.70
Shares:52.57M
Float Shares:51.78M
Volume Ratio:0.84
T/O Rate:1.18%
Dividend:0.32
Dividend Rate:0.35%
EPS(TTM):4.16
EPS(LYR):1.08
ROE:10.04%
ROA:5.17%
PB:2.11
PE(LYR):85.00

Loading ...

Press Release: Warrior Announces Regular Quarterly Cash Dividend

Dow Jones
·
Jul 29

Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC

GlobeNewswire
·
Jul 22

Coal Sector Urges Trump Administration to Provide Financing for Existing, New Power Plants

Reuters
·
Jul 22

Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology

GlobeNewswire
·
Jul 20

3 U.S. Manufacturing Stocks Investors Are Watching As Brazil Tariffs Hit

Simply Wall St.
·
Jul 20

Warrior Met Coal Schedules Q2 Earnings Release, Investor Call

Reuters
·
Jul 16

Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer

GlobeNewswire
·
Jul 14

Blue Creek Completion and Supply Constraints Could Be A Game Changer For Warrior Met Coal (HCC)

Simply Wall St.
·
Jul 12

China Producer Price Pressure Puts Silvercorp Metals And Mining Stocks In Focus

Simply Wall St.
·
Jul 10

HCC Healthcare Signs Business Combination Agreement with RF Acquisition Corp III to Pursue Nasdaq Listing

GlobeNewswire
·
Jul 10

Warrior Met Coal (HCC) Gets a Buy from Jefferies

TIPRANKS
·
Jul 09

RBC Capital Sticks to Their Hold Rating for Warrior Met Coal (HCC)

TIPRANKS
·
Jul 09

Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027

GlobeNewswire
·
Jul 06

Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease

GlobeNewswire
·
Jul 01

3 US Manufacturing Stocks Tied To Onshoring And Trade Tariff Shifts

Simply Wall St.
·
Jul 01

Warrior Met Coal is Maintained at Buy by UBS

Dow Jones
·
Jul 01

UBS Adjusts Price Target on Warrior Met Coal to $100 From $102, Maintains Buy Rating

MT Newswires Live
·
Jun 30

UBS Keeps Their Buy Rating on Warrior Met Coal (HCC)

TIPRANKS
·
Jun 30

Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology

GlobeNewswire
·
Jun 26

HENLIUS Announces First US Patient Dosed in Global Phase 1 Trial for HLX13, an Ipilimumab Biosimilar, in First-Line Unresectable Advanced Liver Cancer

Stock News
·
Jun 25